Journal of Clinical Oncology
Articles in this Issue
Indefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non–small cell lung cancer.
8590 Background: Clinical trials of immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (mNSCLC)...
Predictive and prognostic value of MRI radiomics in patients with hormone-receptor–positive, HER2-negative breast cancer: A multicenter study.
e12559 Background: Treatment decisions for patients (pts) with early-stage hormone receptor-positive, human epidermal grow...
Real-world assessment of the impact of neighborhood vulnerabilities on prostate cancer outcomes in the Medstar Health Network.
e17140 Background: The disparities in prostate cancer (PC) treatment outcomes are thought to be multifactorial, resulting...
Prospective prostate cancer screening in germline pathogenic variant carriers: The PATROL study.
10505 Background: Germline pathogenic variants (gPV) in prostate cancer (PCa) risk genes are associated with aggressive di...
Impact of concurrent tissue (TBx) and liquid (LBx)–based comprehensive genomic profiling (CGP) on biomarker detection and first-line (1L) treatment in metastatic CRC (mCRC).
e15619 Background: While biomarker testing to inform the use of anti-EGFR therapies in mCRC has long been a guideline-reco...
Impact of NCCN-guided training on large language model performance in mNSCLC.
8535 Background: Publicly available large language models (LLMs) such as ChatGPT may support clinical decision-making in p...
Extreme persistence of polyclonal CD8⁺ CAR T cells as a driver of marrow failure, neurotoxicity, and fatal immune collapse after ciltacabtagene autoleucel.
2561 Background: BCMA-directed chimeric antigen receptor (CAR) T-cell therapies induce deep responses in relapsed/refracto...
Comparative efficacy and safety of anti-HER2 neoadjuvant therapy in early-stage HER2-positive breast cancer: A real-world multicenter analysis.
e12668 Background: For patients with early-stage HER2-positive breast cancer, neoadjuvant therapy represents a cornerstone...
Real-world outcomes of dual checkpoint inhibition (nivolumab + ipilimumab) versus anti-PD-1 monotherapy in metastatic uveal melanoma: Impact of local therapy and adjusted survival analysis—A multicenter retrospective study in Russia.
9548 Background: Metastatic uveal melanoma (mUM) remains a rare and aggressive malignancy. Immune checkpoint inhibitors (I...
Safety-net coverage instability during cancer care and association with overall survival.
11090 Background: Means-tested (contingent on income) financial programs for uninsured individuals, such as Medicaid and c...
Current threshold of measurable disease in AL amyloidosis clinical trials.
7547 Background: Eligibility for clinical trials in AL amyloidosis requires measurable disease to ensure that the hematolo...
iMARIX for primary and secondary central nervous system lymphomas.
7086 Background: The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is used in relapsed/resistant central nervous syste...
Single-cell profiling of the tumor microenvironment in pMMR/MSS rectal cancer treated with neoadjuvant PD-1 inhibitor combined with FOLFOXIRI and radiotherapy: Insights from the PANFORTE trial.
3647 Background: Programmed cell death-1 (PD-1) inhibitor-based combination therapies have emerged as a promising neoadjuv...
Prevalence of microsatellite stable Lynch syndrome and universal germline testing: A pan-cancer analysis of 246,694 patients.
10613 Background: Lynch Syndrome (LS) is an inherited cancer syndrome that confers up to a 60% lifetime risk of colorectal...
Predictors of mortality in hospitalized patients with metastatic non-small cell lung cancer (mNSCLC) with or without idiopathic pulmonary fibrosis (IPF).
e20703 Background: mNSCLC is associated with poor survival, with 5-year rates < 15%. Concurrent IPF further worsens pro...
Behavioral gains offset by metabolic drift: A 34-year global profile of breast cancer risk attribution.
e12765 Background: Breast cancer (BC) remains one of the most common malignancies globally and a leading cause of female m...
Trends in pediatric and adolescent thyroid carcinoma incidence and survival in the United States, 2001-2022.
e18102 Background: Thyroid carcinoma incidence in children, adolescents, and young adults has changed substantially over r...
Molecular characteristics and outcomes of a real-world cohort of carcinoma of unknown primary determined by tissue-of-origin assays.
3076 Background: Carcinoma of unknown primary (CUP) increasingly intersects with precision oncology as molecular profiling...
Impact of prior exposure to erythropoiesis-stimulating agents (ESA) on thromboembolic events in patients with myelodysplastic syndromes receiving luspatercept: A real-world TriNetX-based study.
e18585 Background: Luspatercept demonstrated superior transfusion independence over ESAs in ESA-naive Myelodysplastic Synd...
Beyond hematologic malignancies: Clonal hematopoiesis of indeterminate potential and the risk of solid tumors in the UK biobank.
10502 Background: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by soma...
Efficacy and safety of tremelimumab plus durvalumab (STRIDE) versus durvalumab monotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis.
e14577 Background: Durvalumab monotherapy and the STRIDE regimen (tremelimumab plus durvalumab) are approved immunotherapy...
The oral medicine–oncology nexus: Periodontal disease as a predictor of survival and complications in immunotherapy-treated melanoma.
e21599 Background: Immune checkpoint inhibitors have transformed melanoma treatment, but comorbidities like periodontal di...
A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2-negative gastroesophageal adenocarcinomas.
TPS4246 Background: Gastroesophageal adenocarcinoma (GEA) is a major cause of global cancer-related mortality. A common st...
Pan-cancer landscape and real-world management of BRAF non-V600E and MAP2K1 alterations: Analysis from the WAYFIND-R registry.
3080 Background: While targeted therapies have revolutionized the management of BRAF V600E-mutant tumors, non-V600E BRAF a...
Compartment-specific spatial transcriptomics to reveal microenvironmental programs driving omental metastasis in high-grade serous ovarian cancer.
e17601 Background: High-grade serous ovarian cancer (HGSOC) frequently metastasizes to the omentum, yet spatially distinct...